Getting to zero HIV deaths: Progress, challenges and ways forward

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Ford, Nathan ^a   Vitoria, Marco ^a   Hirnschall, Gottfried ^a   Doherty, Meg ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; EARLY INTERVENTION; EUROPE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MORTALITY; PATIENT IDENTIFICATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SELF EVALUATION; SOUTH AFRICA;

HIV INFECTIONS; HUMANS; INCIDENCE; MORTALITY;

EID: 84891715273     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18927     Document Type: Review

References (36)

1. Morgan D, Maude GH, Malamba SS, Okongo MJ, Wagner HU, Mulder D, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet. 1997;350:245-50.
2. Anon. Global update on HIV Treatment 2013: Results, Impact and Opportunities. WHO report, in partnership with UNICEF and UNAIDS. Geneva: WHO; 2013.
3. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
4. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
5. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper C, et al. Life expectancy of persons receiving combination antiretroviral therapy in lowincome countries: a cohort analysis from Uganda. Ann Intern Med. 2011; 155:209-16.
6. Bor J, Herbst A, Newell M-L, Barninghausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961-5.
7. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the GBD 2010. AIDS. 2013. [epub ahead of print].
8. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4+ cell count at presentation to HIV care, 1992-2011. Clin Infect Dis. 2013;57:1027-37.
9. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12:61-4.
10. Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, Salvador FD, Launay O, et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr. 2013;64: 197-203.
11. de Olalla PG, Manzardo C, Sambeat MA, Ocana I, Knobel H, Humet V, et al. Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009. AIDS Res Ther. 2011;8:22.
12. Zoufaly A, an der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L, et al. Late presentation for HIV diagnosis and care in Germany. HIV Med. 2012;13:172-81.
13. Geng EH, Hunt PW, Diero LO, Kimaiyo S, Somi GR, Okong P, et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc. 2011;14:46.
14. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-57.
15. Attia A, Huet C, Anglaret X, Toure S, Ouassa T, Gourvellec G, et al. HIV-1-related morbidity in adults, Abidjan, Cote d'Ivoire: a nidus for bacterial diseases. J Acquir Immune Defic Syndr. 2001;28:478-86.
16. Marshall CS, Curtis A, Spelman T, O'Brien DP, Greig J, Shanks L, et al. Impact of HIV-associated conditions on mortality in people commencing antiretroviral therapy in resource limited settings. PLoS One. 2013;8:e68445.
17. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563-72.
18. Palella FJ, Jr, Baker RK, Moorman AC, Chmiel JS,Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34.
19. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14:195-207.
20. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25:4-9.
21. Grinsztejn B, Luz PM, Pacheco AG, Santos DVG, Velasque L, Moreira R, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART Era. PLoS One. 2013;8(4):e59768.
22. Anon. Consolidared guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2013.
23. Xu Y, Zhang Z, Li D, Liu Y, Pan SW, Qi X, et al. Willingness to use the oral fluid HIV rapid test among men who have sex with men in Beijing, China. PLoS One. 2013;8(5):e64652.
24. Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman A, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10: e1001496.
25. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8:e1001056.
26. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha B, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378:1572-9.
27. Muhamadi L, Tumwesigye NM, Kadobera D, Marrone G,Wabwire-Mangen F, Pariyo G, et al. A single-blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda. Trials. 2011;12:184.
28. Macpherson P. Home assessment and initiation of ART following HIV self-testing: a cluster-randomized trial to improve linkage to ART in Blantyre, Malawi. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta 3-6 March; 2013. Abstract 95LB.
29. Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013;6: CD009987.
30. Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8:e56088.
31. Decroo T, Rasschaert F, Telfer B, Remartinez D, Laga M, Ford N. Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health. 2013;5:169-79.
32. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung M, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838-45.
33. Ford N, Roberts T, Calmy A. Viral load monitoring in resource-limited settings: a medical and public health priority. AIDS. 2012;26(13):1719-20.
34. African Society for Laboratory Medicine. Viral load monitoring in African HIV treatment programmes. Cape Town, South Africa: African Society for Laboratory Medicine; 2013.
35. Chamie G, Kwarisiima D, Clark TD, Kabami J, Jain V, Geng E, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012;7(8):e43400.
36. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis. 2013;57(Suppl 2):S118-24.